- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
REGN Market Currents
more »
-
May 8 An FDA panel votes unanimously against approval for Regeneron's (REGN -0.1%) Arcalyst, saying it's unsafe for the treatment of gout flares. (transcript)
Comment![Healthcare, Breaking News]
REGN in Focus
more »
REGN Related Articles
more »
REGN News
more »
-
at CNBC.com (Apr 27, 2012)
-
at CNBC.com (Mar 29, 2012)
-
at CNBC.com (Mar 26, 2012)
-
at MarketWatch.com (Mar 13, 2012)
-
at CNBC.com (Feb 22, 2012)
REGN Press Releases and Filings
more »
-
PR Newswire (May 10, 2012)
-
PR Newswire (May 9, 2012)
-
PR Newswire (May 8, 2012)
-
PR Newswire (May 8, 2012)
-
PR Newswire (Apr 26, 2012)
REGN Latest Transcript
more »
-
Thu, Apr 26
REGN Cramer
more »
REGN Instablog posts
more »
REGN vs. ETF Alternatives
Company Description
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. We currently have one marketed product: ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is... More
